# A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

> **NCT06166056** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 45 (estimated)

## Conditions studied

- Bronchiectasis

## Interventions

- **DRUG:** CHF6333
- **DRUG:** CHF6333 Placebo

## Key facts

- **NCT ID:** NCT06166056
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06166056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06166056, "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06166056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*